Drug Price Trends for MUCUS RLF DM MAX ER

Average Pharmacy Cost for MUCUS RLF DM MAX ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MUCUS RLF DM MAX ER 1200-60 MG	00536-1213-88	0.54786	EACH	2024-12-18
MUCUS RLF DM MAX ER 1200-60 MG	70000-0464-01	0.54786	EACH	2024-12-18
MUCUS RLF DM MAX ER 1200-60 MG	70000-0464-02	0.54786	EACH	2024-12-18
MUCUS RLF DM MAX ER 1200-60 MG	00536-1213-88	0.55084	EACH	2024-11-20

Market Analysis and Price Projections for Mucus Relief DM Max ER

Overview of Mucus Relief DM Max ER

Mucus Relief DM Max ER, a combination of dextromethorphan and guaifenesin, is a widely used over-the-counter (OTC) medication designed to relieve coughs and loosen mucus. This medication falls under the category of upper respiratory combinations and is commonly prescribed for symptoms associated with colds, flu, and other respiratory conditions.

Market Size and Growth

The market for expectorant drugs, which includes Mucus Relief DM Max ER, is projected to grow steadily over the coming years. According to market analysis, the expectorant drugs market is expected to reach USD 100 million by 2024 and grow at a Compound Annual Growth Rate (CAGR) of 4.5% to reach USD 120 million by 2029[4].

Regional Market Dominance

North America is anticipated to dominate the market due to the high prevalence of respiratory diseases, the presence of key players, and increasing research and development expenditures. The region's aging population also contributes to the demand for such medications[4].

Key Drivers of Market Growth

Approval and Launch of New Products

The approval and launch of new formulations, such as the FDA-approved Mucinex DM Maximum Strength (guaifenesin and dextromethorphan hydrobromide extended-release tablets), are expected to drive market growth. These new products offer enhanced efficacy and convenience, attracting more consumers[1].

Prevalence of Respiratory Diseases

The high incidence of respiratory diseases such as the common cold, influenza, pneumonia, and chronic obstructive pulmonary disease (COPD) in regions like North America significantly boosts the demand for expectorant drugs like Mucus Relief DM Max ER[4].

Pricing and Cost Analysis

Current Pricing

The cost of Mucus Relief DM Max ER varies depending on the dosage and quantity. For example, the extended-release oral tablet formulation (30 mg-600 mg) can cost around $13 for a supply of 20 tablets. Higher dosages, such as the 60 mg-1200 mg formulation, can range from $16.78 to $20.60 for 14 tablets[2].

Discounts and Patient Assistance

Consumers can benefit from discount cards and patient assistance programs, which can reduce the cost of the medication by up to 80%. These programs are accepted at most major pharmacies across the U.S.[2].

Market Estimation Techniques

Bottom-Up Market Analysis

To estimate the market size and revenue for Mucus Relief DM Max ER, a bottom-up approach is often used. This involves:

• Estimating the potential market size based on the total population and the population in target markets.
• Analyzing the incidence and prevalence of the disease or condition.
• Determining the addressable market size, percentage of diagnosed patients, and percentage of patients treated.
• Conducting penetration, pricing, competitive analysis, compliance analysis, reimbursement analysis, and utilization patterns analysis[3].

Segmentation Analysis

Market segmentation helps refine penetration and share forecasts by identifying different customer segments, such as severely, moderately, and mildly affected patients. This segmentation allows for more focused marketing efforts and better estimation of market share[3].

Competitive Landscape

Major Players

The expectorant drugs market, including Mucus Relief DM Max ER, is moderately concentrated with several key players. Companies like Perrigo Company plc, which received FDA approval for Mucinex DM Maximum Strength, are significant competitors in this market[1][4].

Regulatory Environment

Stringent Regulations

While the market for expectorant drugs is growing, stringent regulations against the use of cough suppressants could impact the growth of the global cough suppressant drugs market. Compliance with these regulations is crucial for maintaining market presence[1].

Consumer Preferences and Behavior

Non-Drowsy Formulations

Consumers increasingly prefer non-drowsy formulations, which allow them to manage their symptoms without the sedative effects. Products like Rite Aid Mucus Relief DM Max, which is non-drowsy, cater to this preference and are likely to see increased demand[5].

Maximum Strength Formulations

Maximum strength formulations, such as Mucus Relief DM Max ER, are in high demand due to their fast and effective relief from severe cough and congestion symptoms. These formulations are often compared to leading national brands and offer similar efficacy at competitive prices[5].

Future Outlook

Growth Drivers Analysis

The future growth of the market will be driven by factors such as the increasing prevalence of respiratory diseases, the launch of new and improved formulations, and the rising demand for non-drowsy and maximum strength medications. Historical penetration of comparable products and physician acceptance will also play a significant role in market expansion[3].

Reimbursement and Commercial Efforts

Reimbursement from key payer groups and commercial efforts, including detailing and sampling, will influence the market penetration of Mucus Relief DM Max ER. Companies will need to map their commercial efforts into physician prescribing behavior to maximize market share[3].

"Respiratory diseases are a significant health concern in North America, with the common cold, influenza, and pneumonia being among the most common causes of illness. For instance, in 2022, according to data published by the Centers for Disease Control and Prevention (CDC), 4.6% of adults in the U.S. reported having been diagnosed with COPD, emphysema, or chronic bronchitis."[4]

Key Takeaways

• The expectorant drugs market, including Mucus Relief DM Max ER, is projected to grow at a CAGR of 4.5% from 2024 to 2029.
• North America is expected to dominate the market due to high prevalence of respiratory diseases and the presence of key players.
• New product approvals and launches, such as Mucinex DM Maximum Strength, drive market growth.
• Consumer preference for non-drowsy and maximum strength formulations is increasing.
• Stringent regulations against cough suppressants could impact market growth.

FAQs

What is Mucus Relief DM Max ER used for?

Mucus Relief DM Max ER is used to temporarily relieve coughs and loosen mucus associated with minor throat and bronchial irritation, such as that caused by a cold.

How much does Mucus Relief DM Max ER cost?

The cost of Mucus Relief DM Max ER varies, but the extended-release oral tablet (30 mg-600 mg) can cost around $13 for a supply of 20 tablets.

Are there any discounts available for Mucus Relief DM Max ER?

Yes, consumers can use discount cards and patient assistance programs to reduce the cost of the medication by up to 80%.

What are the key drivers of the expectorant drugs market growth?

Key drivers include the high prevalence of respiratory diseases, new product approvals, and consumer preference for non-drowsy and maximum strength formulations.

Which region is expected to dominate the expectorant drugs market?

North America is expected to dominate the market due to the high prevalence of respiratory diseases and the presence of key players.

Sources

1. Allied Market Research: Guaifenesin Market Size, Trends | Industry Report 2021 - 2030
2. Drugs.com: Mucus Relief DM Prices, Coupons, Copay Cards & Patient Assistance
3. iHealthcareAnalyst: Revenue Forecasting Techniques for New Pharmaceutical Drugs
4. Mordor Intelligence: Expectorant Drugs Market Size & Share Analysis
5. Rite Aid: Rite Aid Mucus Relief DM Max Cough Suppressant Expectorant, 6 fl oz, 1 Count